Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NYSE:ANVS NASDAQ:ELEV NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.34+0.2%$2.45$0.80▼$3.42$95.92M-0.89154,256 shs7,985 shsANVSAnnovis Bio$1.74-20.9%$2.39$1.11▼$10.54$33.91M1.63476,005 shs5.21 million shsELEVElevation Oncology$0.37$0.37$0.22▼$3.09$21.62M1.481.18 million shsN/AONCYOncolytics Biotech$1.25+0.8%$1.16$0.33▼$1.51$125.45M1.241.01 million shs136,759 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+1.30%-3.32%+5.91%+40.36%+19.49%ANVSAnnovis Bio-2.64%-0.45%-6.55%-18.75%-72.58%ELEVElevation Oncology0.00%0.00%0.00%-3.16%-29.40%ONCYOncolytics Biotech-3.13%-12.68%-10.79%+5.08%-5.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.34+0.2%$2.45$0.80▼$3.42$95.92M-0.89154,256 shs7,985 shsANVSAnnovis Bio$1.74-20.9%$2.39$1.11▼$10.54$33.91M1.63476,005 shs5.21 million shsELEVElevation Oncology$0.37$0.37$0.22▼$3.09$21.62M1.481.18 million shsN/AONCYOncolytics Biotech$1.25+0.8%$1.16$0.33▼$1.51$125.45M1.241.01 million shs136,759 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+1.30%-3.32%+5.91%+40.36%+19.49%ANVSAnnovis Bio-2.64%-0.45%-6.55%-18.75%-72.58%ELEVElevation Oncology0.00%0.00%0.00%-3.16%-29.40%ONCYOncolytics Biotech-3.13%-12.68%-10.79%+5.08%-5.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 2.00Hold$5.50135.55% UpsideANVSAnnovis Bio 2.33Hold$17.33896.17% UpsideELEVElevation Oncology 2.00Hold$2.62616.89% UpsideONCYOncolytics Biotech 2.50Moderate Buy$5.00300.00% UpsideCurrent Analyst Ratings BreakdownLatest ANVS, ELEV, ONCY, and ANEB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ANEBAnebulo PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ANVSAnnovis BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ONCYOncolytics BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/30/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/27/2025ANEBAnebulo PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ANVSAnnovis BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ONCYOncolytics BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/3/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.008/13/2025ONCYOncolytics BiotechLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.008/8/2025ANVSAnnovis BioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/23/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AELEVElevation OncologyN/AN/AN/AN/A$1.02 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.26N/A∞N/AN/A-80.85%-76.33%N/AANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)ELEVElevation Oncology-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%11/4/2025 (Estimated)ONCYOncolytics Biotech-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)Latest ANVS, ELEV, ONCY, and ANEB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/29/2025Q4 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.05N/A-$0.05N/AN/A8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/8/2025Q2 2025ONCYOncolytics Biotech-$0.11-$0.05+$0.06-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A24.5124.51ANVSAnnovis BioN/A7.657.65ELEVElevation Oncology0.6719.4019.40ONCYOncolytics BiotechN/A2.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%ANVSAnnovis Bio15.83%ELEVElevation Oncology83.70%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%ANVSAnnovis Bio20.80%ELEVElevation Oncology8.10%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.08 million7.97 millionNot OptionableANVSAnnovis Bio319.49 million15.43 millionOptionableELEVElevation Oncology4059.22 million54.43 millionOptionableONCYOncolytics Biotech30100.36 million100.26 millionNot OptionableANVS, ELEV, ONCY, and ANEB HeadlinesRecent News About These CompaniesOncolytics Biotech's (ONCY) Sell (E+) Rating Reiterated at Weiss Ratings3 hours ago | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Trading Down 3.1% - Should You Sell?October 10 at 3:19 AM | marketbeat.comOncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration StudySeptember 29, 2025 | prnewswire.comQ3 EPS Estimate for Oncolytics Biotech Reduced by AnalystSeptember 19, 2025 | marketbeat.comOncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 18, 2025 | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Stock Price Down 3.1% - Here's What HappenedSeptember 17, 2025 | marketbeat.comOncolytics Biotech Expands GOBLET Study to U.S., Shows Promising ResultsSeptember 16, 2025 | msn.comOncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site ExpansionSeptember 16, 2025 | prnewswire.comLake Street Keeps Their Buy Rating on Oncolytics Biotech (ONCY)September 10, 2025 | theglobeandmail.comOncolytics Biotech (ONCY) Receives a Hold from JonesTradingSeptember 10, 2025 | theglobeandmail.comBreakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape MarketSeptember 9, 2025 | newswire.caOncolytics Biotech Reports Promising Results in Metastatic Colorectal Cancer StudiesSeptember 8, 2025 | tipranks.comOncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway DiscussionsSeptember 8, 2025 | prnewswire.comOncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal TumorsSeptember 2, 2025 | prnewswire.comCancer Treatment Revolution Drives $903B Market as New Therapies Gain MomentumAugust 28, 2025 | baystreet.caOncolytics Biotech® Announces Upcoming Investor Conferences in SeptemberAugust 28, 2025 | prnewswire.comHere's Why We're Watching Oncolytics Biotech's (NASDAQ:ONCY) Cash Burn SituationAugust 27, 2025 | finance.yahoo.comLake Street Initiates Coverage of Oncolytics Biotech (ONCY) with Buy RecommendationAugust 14, 2025 | msn.comOncolytics Biotech Inc.: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of ShareholdersAugust 12, 2025 | finanznachrichten.deOncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersAugust 11, 2025 | prnewswire.comJonesTrading Remains a Hold on Oncolytics Biotech (ONCY)August 10, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANVS, ELEV, ONCY, and ANEB Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$2.34 +0.01 (+0.21%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Annovis Bio NYSE:ANVS$1.74 -0.46 (-20.91%) As of 10:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Elevation Oncology NASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$1.25 +0.01 (+0.81%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
